87%Confidence
0Views
FDASource
2026-03-15Date
Summary
LEO Pharma recalls Adbry autoinjectors due to wool fiber contamination, a sterility issue that could compromise the biologic's integrity. This Class II recall may disrupt treatment for atopic dermatitis patients and requires investigation into packaging processes.
Actionable: Monitor LEO Pharma's corrective actions and assess any potential supply chain delays for Adbry in the dermatology market.
AI Confidence: 87%
Data Points
firmLEO PHARMA INC
classificationClass II
statusOngoing
distributionNationwide in the USA
productAdbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single do
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now